Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03398434
Recruitment Status : Withdrawn (Trial cancelled before First Patient First Visit (no patient enrolled))
First Posted : January 12, 2018
Last Update Posted : October 8, 2020
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of MAA868 compared to apixaban in patients with atrial fibrillation.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Drug: MAA868 Drug: Apixaban Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a randomized, open-label, blinded endpoint evaluation, active controlled, dose-range finding study.
Masking: Single (Outcomes Assessor)
Masking Description: blinded (with majuscule) endpoint evaluation
Primary Purpose: Basic Science
Official Title: A Multicenter, Randomized, Open-label, Active-controlled, Dose-range Finding Study to Assess the Pharmacodynamic Parameters, Safety and Tolerability of MAA868 and Its Effect on Thrombogenesis Biomarkers Compared to Apixaban in Patients With Atrial Fibrillation
Estimated Study Start Date : October 16, 2018
Estimated Primary Completion Date : November 28, 2019
Estimated Study Completion Date : January 30, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Apixaban

Arm Intervention/treatment
Experimental: MAA868 low dose regimen
patients receive dose monthly.
Drug: MAA868
3 MAA868 doses, single administration, subcutaneous,

Experimental: MAA868 middle dose regimen
patients receive dose monthly.
Drug: MAA868
3 MAA868 doses, single administration, subcutaneous,

Experimental: MAA868 high dose regimen
patients receive dose monthly.
Drug: MAA868
3 MAA868 doses, single administration, subcutaneous,

Active Comparator: Apixaban
Apixaban 5 mg b.i.d
Drug: Apixaban
Apixaban 5 mg b.i.d




Primary Outcome Measures :
  1. number of patients achieving FXI inhibition ≥ 80% at trough after monthly dosing at 3 dose levels of MAA868 inhibition [ Time Frame: month 3 ]
    Occurrence of achieving ≥ 80% inhibition of FXI (< 20% free FXI) following 3 months of treatment.


Secondary Outcome Measures :
  1. number of patients achieving FXI inhibition ≥ 80% at trough after the first and second dose at 3 dose levels of MAA868 [ Time Frame: Month 1 and 2 ]
    Occurrence of achieving ≥ 80% inhibition of FXI (< 20% free FXI) at trough on Month 1 and Month 2

  2. Number of patients with incidence of major or clinically relevant non-major (CRNM) bleeding events during the treatment period. [ Time Frame: day 1 to day 91 ]
    Incidence of major or clinically relevant non-major bleeding events

  3. the effect of MAA868 on D dimer and other thrombogenesis biomarkers as indicators of efficacy compared to compotator [ Time Frame: Days 31, 61 and 91 ]
    Change from baseline to Day 31, Day 61 and Day 91 in thrombogenesis biomarkers (D-dimer, prothrombin fragment 1.2 (F1.2), thrombin-antithrombin III-complexes (TAT), fibrinogen).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients ≥ 55 and < 85 years old
  • Body weight between 50 and 130 kg inclusive
  • Atrial fibrillation or atrial flutter, as documented by electrocardiography
  • CHA2DS2-VASc risk score ≥ 2 for male and female patients. Male patients with CHA2DS2VASc risk score of 1 can be included if anticoagulation therapy is warranted.
  • Either anticoagulant-naïve or receiving a stable treatment of a recommended dose of a new oral anticoagulant (NOAC) over the 8 weeks prior to screening.

Exclusion Criteria:

  • History of stroke, transient ischemic attack or systemic embolism
  • History of major bleeding during treatment with an anticoagulant or antiplatelet therapy in the last 12 months
  • History of traumatic or non-traumatic intracranial, intraspinal or intra-ocular bleeding
  • Known bleeding diathesis or any known active bleeding site at screening or baseline
  • Family history of bleeding disorder
  • Known active GI lesions predisposing to bleeding events
  • Myocardial infarction, unstable angina pectoris or coronary artery bypass graft (CABG) surgery within 12 months prior to the screening period
  • Known hemodynamically significant valvular heart disease
  • Uncontrolled hypertension defined as SBP/DBP ≥ 160/100 mmHg at the screening visit
  • Heart failure NYHA class IV in the 3 months prior to the screening visit
  • Dual antiplatelet therapy. Treatment with a P2Y12 inhibitor or low dose aspirin (≤ 100 mg/d) is allowed but not both.
  • Severe renal impairment (creatinine clearance < 30 mL/min) at the screening visit
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03398434    
Other Study ID Numbers: CMAA868A2202
2017-002741-29 ( EudraCT Number )
First Posted: January 12, 2018    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
MAA868
apixaban
atrial fibrillation
anticoagulant
Factor XI
D-dimer
systemic thromboembolic events
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Apixaban
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticoagulants